Adipose tissue-heart crosstalk as a novel target for treatment of cardiometabolic diseases

Cardiometabolic disorders, such as diabetes, obesity, or metabolic syndrome, are often considered as key comorbidities, leading to the development of different forms of cardiovascular diseases such as heart failure or diabetic cardiomyopathy. Although the causal relationship between the pathophysiological status of white adipose tissue (WAT) and cardiac lipotoxicity is still elusive, elevated lipolytic rate in WAT has been demonstrated to participate in the overall augmentation of plasma lipid levels, as observed in most of the patients suffering from heart failure. In the present overview, we discuss current therapeutic approaches, as well as new treatment options targeting lipolysis and cardiac lipid metabolism in different forms of heart failure and diabetic cardiomyopathy.

Automated summary

The translated content mainly discusses how cardiometabolic disorders lead to the development of cardiovascular diseases, particularly the relationship between white adipose tissue and cardiac lipotoxicity. In addition, treatment options for heart failure and diabetic cardiomyopathy are also discussed.